Lyell Immunopharma
LYEL
LYEL
75 hedge funds and large institutions have $689M invested in Lyell Immunopharma in 2022 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 19 reducing their positions, and 16 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
0.08% more ownership
Funds ownership: 2.07% → 2.15% (+0.08%)
5% less funds holding
Funds holding: 79 → 75 (-4)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
Holders
75
Holding in Top 10
4
Calls
$3.92M
Puts
$45K
Top Buyers
| 1 | +$14.3M | |
| 2 | +$12.1M | |
| 3 | +$11.3M | |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.6M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.75M |
Top Sellers
| 1 | -$1.42M | |
| 2 | -$1.28M | |
| 3 | -$1.26M | |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$1.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.09M |